Literature DB >> 25362778

[Drug-induced interstitial lung diseases].

Philippe Bonniaud, Marjolaine Georges, Nicolas Favrolt, Philippe Camus.   

Abstract

Drug-induced infiltrative lung disease may manifest as variable clinical radiological patterns, including subacute or chronic interstitial pneumonia, pulmonary fibrosis, eosinophilic pneumonia, organising pneumonia, pulmonary edema, or sarcoidosis. A large amount of drugs have been incriminated, including those used in cardiovascular diseases (amiodarone, statins and angiotensin converting enzyme inhibitors), antibiotics (minocycline, nitrofurantoin), most of anticancer drugs (and especially chemotherapy and chest radiation), treatment of rheumatoid arthritis, as well as more recent drugs. A high index of suspicion is therefore required in any patient with infiltrative lung disease and the web-based tool www.pneumotox.com will help to list possible causative drugs. The following steps are necessary: history and timing of drug exposure, clinical and imaging pattern, exclusion of other causes of infiltrative lung disease, improvement following drug discontinuation. Rechallenge, dangerous, is not recommended.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25362778

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  6 in total

Review 1.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

2.  Fibrotic Lung Toxicity Induced by Hydroxycarbamide.

Authors:  Elena Bargagli; Marco Palazzi; Francesco Perri; Elena Torricelli; Elisabetta Rosi; Alessandra Bindi; Massimo Pistolesi; Luca Voltolini
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

3.  Interstitial pneumonia induced by cyclophosphamide: A case report and review of the literature.

Authors:  Panpan Qian; Chun Hong Peng; Xianwei Ye
Journal:  Respir Med Case Rep       Date:  2019-01-26

Review 4.  Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis.

Authors:  Myriam Aburto; Inmaculada Herráez; David Iturbe; Ana Jiménez-Romero
Journal:  Med Sci (Basel)       Date:  2018-09-04

Review 5.  Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Authors:  Antonio Cuneo; Giovanni Barosi; Romano Danesi; Stefano Fagiuoli; Paolo Ghia; Alfredo Marzano; Marco Montillo; Venerino Poletti; Pierluigi Viale; Pier Luigi Zinzani
Journal:  Hematol Oncol       Date:  2018-09-05       Impact factor: 5.271

Review 6.  A case report and literature review: previously excluded tuberculosis masked by amiodarone induced lung injury.

Authors:  Egle Karinauske; Silvijus Abramavicius; Greta Musteikiene; Edgaras Stankevicius; Jurgita Zaveckiene; Vidas Pilvinis; Edmundas Kadusevicius
Journal:  BMC Pharmacol Toxicol       Date:  2018-12-29       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.